Here is the design of a clinical trial:

Official Title: The Clinical Carbetocin Myocardium Trial Part 2

Included conditions:
- Pregnancy Complications

Study Armgroups:
- {'label': 'Oxytocin', 'type': 'ACTIVE_COMPARATOR', 'description': 'Oxytocin 2.5 U i.v.', 'interventionNames': ['Drug: Oxytocin']}
- {'label': 'Carbetocin', 'type': 'EXPERIMENTAL', 'description': 'Carbetocin 100 µg i.v.', 'interventionNames': ['Drug: Carbetocin']}

Interventions:
- {'type': 'DRUG', 'name': 'Oxytocin', 'description': 'Oxytocin 2.5 U i.v.', 'armGroupLabels': ['Oxytocin']}
- {'type': 'DRUG', 'name': 'Carbetocin', 'description': 'Carbetocin 100 µg i.v.', 'armGroupLabels': ['Carbetocin']}

Primary Outcomes:
- {'measure': 'Plasma Concentration Troponin I', 'description': 'Group difference in Troponin I', 'timeFrame': '8 hours'}

Please estimate the sample size based on the assumption: 
80% power, significance level of 5%, adjustments for unequal variances, and a low expected dropout rate.
Power and sample size considerations
        The sample size required for our current study was calculated using data from a pilot study of 40 patients, in which the largest difference in plasma troponin I concentration was found at 10 hours, with a mean Â± standard deviation change from baseline of 0.41 Â± 0.79 ng/L in the carbetocin group versus 1.78 Â± 4.48 in the oxytocin group. The sample size calculation was thus based on 80% power to detect a between-group difference in change from baseline to 10 hours of 1.37, to be analysed using a two-sample T-test with adjustments for unequal variances. With a significance level of 5%, our study will need to include 178 patients (89 in each treatment group) in this confirmatory trial. To adjust for loss of information from missing values and patient dropouts, 240 women will be enrolled. The drop-out rate after enrolment is expected to be low as the duration of the study is short.